Silvestre Vicent

This study shows that combining AXL inhibition with RAS or ERK inhibitors enhances efficacy in KRAS-mutant cancers by overcoming resistance mechanisms.

This study shows that targeted KRAS(G12V) degradation causes durable lung adenocarcinoma regression in mice, with tumor relapse linked to proteolysis machinery dysregulation.

This study evaluates how scaffold composition affects PDAC organoid phenotype, metabolism, and drug resistance, finding that collagen-Matrigel mixtures best mimic invasive tumors.

GeNNius uses a graph neural network to predict drug-target interactions more efficiently and accurately than existing methods across multiple datasets.